Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6324878 | 0.90 | CDK4 (0.37) | PARP1HTR2CMTNR1AMTNR1BCCNE2 | |
| SCHEMBL6327649 | 0.82 | CDK4 (0.36) | PARP1MTNR1AMTNR1BCDK4CCND1 | |
| SCHEMBL2344849 | 0.81 | PARP1 (0.44) | PARP1HTR2CMTNR1AMTNR1B | |
| SCHEMBL6328642 | 0.80 | PARP1 (0.37) | PARP1MTNR1AMTNR1BCDK4CCND1 | |
| SCHEMBL1719811 | 0.79 | MTNR1A (0.51) | PARP1HTR2CMTNR1AMTNR1B | |
| SCHEMBL5768646 | 0.78 | MTNR1A (0.47) | PARP1HTR2CMTNR1AMTNR1B | |
| SCHEMBL10123732 | 0.77 | PARP1 (0.41) | PARP1HTR2C | |
| SCHEMBL13056761 | 0.77 | PARP1 (0.41) | PARP1MTNR1AMTNR1B | |
| SCHEMBL10123738 | 0.76 | PARP1 (0.41) | PARP1HTR2C | |
| SCHEMBL6326991 | 0.76 | FKBP1A (0.33) | PARP1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6894116-B2 | S,S′-bis-(α, α′—disubstituted—α″—acetic acid)—trithiocarbonates and polymers thereof for toughening thermosetting resins | NOVEON IP HOLDINGS CORP. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-6743785-B2 | KINASE INHIBITORS; ANNULATED PYRROLE AND INDOLE RINGS; PYRROLO (3,2,1-HI)INDOLES; 3-(5,5-DIMETHYL-5,6-DIHYDRO-4H-PYRROLO (3,2,1-IJ)QUINOLIN-1-YL)-4-(1,2,3,4-TETRAHYDRO-(1,4) DIAZEPINO(6,7,1-HI)INDOL-7-YL)-PYRROLE-2,5-DIONE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| EP-1250334-B1 | Medicaments useful for the treatment of proliferative diseases | LILLY CO ELI (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030187138-A1 | S,s' -bis-(alpha, alpha' - disubstituted - alpha\" - acetic acid) - trithiocarbonates and polymers thereof for toughening thermosetting resins | LUBRIZOL ADVANCED MATERIALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | disclosed |
| EP-1242420-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044247-A2 | AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-5280068-A | Containing carboxy, amine, or epoxy terminated polymer | THE B.F. GOODRICH COMPANY (US) | 1994-01-18 | — | — | US | disclosed |
| EP-0526575-A1 | EPOXY RESIN SYSTEMS MODIFIED WITH LOW VISCOSITY STATISTICAL MONOFUNCTIONAL REACTIVE POLYMERS | THE B.F. GOODRICH COMPANY (US) | 1993-02-10 | — | — | EP | disclosed |
| US-5157077-A | Carboxyl, amine or epoxy-terminated reactive polymers | THE B. F. GOODRICH COMPANY (US) | 1992-10-20 | — | — | US | disclosed |
| US-5140068-A | Toughness, adhesion, elongation | THE B. F. GOODRICH COMPANY (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1991017213-A1 | EPOXY RESIN SYSTEMS MODIFIED WITH LOW VISCOSITY STATISTICAL MONOFUNCTIONAL REACTIVE POLYMERS | THE B.F. GOODRICH COMPANY (US) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092676-A1 | Agents and method for the treatment of proliferative diseases | MKI67, CDKN1A, CDK4 | PARP1 579/4885HTR2C 4329/4885MTNR1A 1002/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | PARP1 516/4885HTR2C 4346/4885MTNR1A 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.